Jade Biosciences, Inc. (JBIO)
NASDAQ • Healthcare
Last close at September 22, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 12
in 50 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Jade Biosciences’ earnings missed expectations, with EPS of -$0.76 trailing the -$0.64 estimate by -$0.12, based on preliminary results for the second fiscal quarter of 2026 that were reported August 10, 2026. The biotechnology company generated a GAAP operating loss of about $58.9 million, and net income was a loss of roughly $55.8 million, down 73.5% from a loss of about $32.1 million a year ago. Cash burn remained evident, with negative operating cash flow of around $43.7 million during the quarter as the company continues advancing its kidney-disease pipeline, including lead program JADE-001 for IgA nephropathy alongside preclinical programs JADE-002 and JADE-003. Consensus for the next period calls for EPS of -$0.73.
About Jade Biosciences, Inc.
Jade Biosciences, Inc. is a NASDAQ-listed biotechnology company developing kidney-disease and earlier-stage therapeutic candidates. Trading as JBIO, the company is a small-cap healthcare name whose pipeline centers on JADE-001 for immunoglobulin A, or IgA, nephropathy, alongside two preclinical programs, JADE-002 and JADE-003.
Today's Snapshot
The day ended with JBIO slightly higher at 16.76, while its sector was firmer. Trading was lighter than usual, with volume about half of its usual level.
Trading Volume
Below 10d avg (1.2M)
643.5K
vs S&P 500 Today
Inline with Market
-0.02%
Updated: September 22, 2026 at 20:23 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$17.52 - $19.88Sell
- RSI (14)30.37Neutral
- Stochastic %K (14, 3, 3)11.19Buy
- MACD Level (12, 26)-1.24Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.